- Earlier in June 2026, BioMarin Pharmaceutical reported new data at ENDO 2026 showing sustained growth benefits and a favorable safety profile for VOXZOGO in hypochondroplasia, alongside encouraging Phase 1 results for long-acting BMN 333 in achondroplasia that supported weekly dosing.
- The updates not only underline VOXZOGO’s potential to reach thousands of additional rare-disease patients but also highlight BMN 333 as a possible next-generation option in achondroplasia care.
- We’ll now examine how VOXZOGO’s sustained growth data in hypochondroplasia could influence BioMarin’s broader investment narrative and future earnings power.
AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
BioMarin Pharmaceutical Investment Narrative Recap
To own BioMarin today, you need to believe VOXZOGO can anchor a rare-disease growth story while newer candidates like BMN 333 extend that franchise, even as pricing and regulatory scrutiny weigh on margins. The ENDO 2026 data strengthens the VOXZOGO expansion narrative and slightly improves visibility around BMN 333, but it does not materially change the near term focus on execution around upcoming hypochondroplasia filings and ongoing pressure on profitability.
Among recent events, the May 2026 CANOPY-HCH-3 Phase 3 win in hypochondroplasia pairs directly with the ENDO 2026 extension data, giving BioMarin both pivotal and longer term support for VOXZOGO in this new population. Together, they frame a key catalyst in the next year as regulators review potential label expansion while investors weigh that opportunity against rising R&D and SG&A needs and sensitivity to rare disease pricing reforms.
Yet while the growth story looks appealing, investors should be aware that...
Read the full narrative on BioMarin Pharmaceutical (it's free!)
BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029.
Uncover how BioMarin Pharmaceutical's forecasts yield a $87.85 fair value, a 57% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming only about US$4.5 billion of 2029 revenue and US$752.9 million of earnings, so if you are worried about VOXZOGO dependence and pricing pressure, this new VOXZOGO and BMN 333 data may eventually shift those more cautious narratives in ways worth comparing side by side.
Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.
Ready For A Different Approach?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
- Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com